Trastuzumab bei Patientinnen mit metastasiertem Mammakarzinom über die Erstlinientherapie hinaus

Authors

Debu Tripathy, University of Texas MD Anderson Cancer Center, USA
Dennis Slamon, University of California, USA.
Michael Cobleigh, Rush University Medical Center, USA
Arnold Arnold, Northwestern University, USA.
Mansoor SalehFollow
Joyce Mortimer, University of California, SA
Michael Murphy, University of California, USA.
Sandra Steward, University of California, USA.

Document Type

Article

Department

Haematology and Oncology, East Africa

Abstract

This study focuses on the extended use of Trastuzumab in the treatment of HER2-positive metastatic breast cancer beyond first-line therapy. It highlights the significance of HER2-targeted therapies, particularly Trastuzumab, in improving clinical outcomes such as progression-free survival (PFS) and overall survival (OS). The article discusses the combination of Trastuzumab with other therapeutic agents like Pertuzumab and Docetaxel, emphasizing its role in dual HER2 blockade. It also addresses the challenges of treatment resistance and the need for continuous HER2 inhibition in the metastatic setting. The study underscores the necessity of developing new HER2-targeted therapies to manage resistance and improve patient prognosis

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

J Clin Oncol

DOI

https://doi.org/10.1007/s00761-004-0731-2

Recommended Citation

Tripathy, D., Slamon, D., Cobleigh, M., Arnold, A., Saleh, M., Mortimer, J., Murphy, M., Steward, S. (2004). Trastuzumab bei Patientinnen mit metastasiertem Mammakarzinom über die Erstlinientherapie hinaus. J Clin Oncol, 17, 2639-2648.
Available at: https://ecommons.aku.edu/eastafrica_fhs_mc_haematol_oncol/58